| INF |
Table INF-0. Bibliographic references
|
table |
| INF |
Table INF-1. Prevalence of HIV infection among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
|
table |
| INF |
Table INF-2. Prevalence of HCV antibody among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
|
table |
| INF |
Table INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU, 2006 or most recent year available — Summary table by country
|
table |
| INF |
Table INF-18. Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 2001 to 2006, samples with average prevalence above 5 %
|
table |
| INF |
Table INF-19. Trends in HCV antibody prevalence in national and subnational samples of injecting drug users 2001 to 2006, countries with average prevalence above 50 %.
|
table |
| INF |
Table INF-104. HIV infections newly diagnosed in injecting drug users, by year of report from 1992 to 2006, (a) cases per million population, (b) number of cases and (c) population sizes
|
table |
| INF |
Table INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all cases with known risk factor
|
table |
| INF |
Table INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU: number of IDU cases and percentage of IDUs amongst all notified cases with known risk factor
|
table |
| INF |
Table INF-107. Incidence studies of hepatitis C virus infection among injecting drug users in the EU
|
table |
| INF |
Table INF-108. Prevalence of HIV infection (percentage) among injecting drug users, 1991 to 2007
|
table |
| INF |
Table INF-109. Prevalence of HIV infection (percentage) among injecting drug users under age 25, 1991 to 2007
|
table |
| INF |
Table INF-110. Prevalence of HIV infection (percentage) among new injecting drug users (injecting less than 2 years), 1991 to 2006
|
table |
| INF |
Table INF-111. Prevalence of hepatitis C infection (percentage) among injecting drug users, 1991 to 2007
|
table |
| INF |
Table INF-112. Prevalence of hepatitis C infection (percentage) among injecting drug users under age 25, 1991 to 2007
|
table |
| INF |
Table INF-113. Prevalence of hepatitis C infection (percentage) among new injecting drug users (injecting less than 2 years), 1991 to 2006
|
table |
| INF |
Table INF-114. Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users, 1991 to 2006
|
table |
| INF |
Table INF-115. Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users, 1991 to 2006
|
table |
| INF |
Table INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006
Part (i) Prevalence of HIV infection (percentage) among injecting drug users in prison
|
table |
| INF |
Table INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006
Part (ii) Prevalence of hepatitis C infection (percentage) among injecting drug users in prison
|
table |
| INF |
Table INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006
Part (iii) Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users in prison
|
table |
| INF |
Table INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2006
Part (iv) Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users in prison
|
table |
| INF |
Figure INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million, 1996 to 2006
|
figure |
| INF |
Figure INF-2. HIV infections newly diagnosed in injecting drug users, by year of report, by country, cases per million, 1996–2006
|
figure |
| INF |
Figure INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage
Part (i) All injecting drug users, 2005 and 2006
|
figure |
| INF |
Figure INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage
Part (ii) Young injecting drug users (under age 25), 2005 to 2006
|
figure |
| INF |
Figure INF-6. Estimated HCV antibody prevalence among injecting drug users — studies with national and subnational coverage
Part (i) Sample estimates, 2005 to 2006
|
figure |
| INF |
Figure INF-6. Estimated HCV antibody prevalence among injecting drug users — studies with national and subnational coverage
Part (ii) Estimates for the sub-sample of young injecting drug users (under age 25), 2005 to 2006
|
figure |
| INF |
Figure INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2005 to 2006, where data are available
Part (i) Percentage positive for ever infected (aHBc)
|
figure |
| INF |
Figure INF-9. Prevalence of markers of HBV infection estimated among national and subnational samples of injecting drug users 2005 to 2006, where data are available
Part (ii) Percentage positive for current infection (HBsAg)
|
figure |
